The PIONEER 6 trial
Update 06-11-2019 | Oral semaglutide falls just short of cardioprotection in event-driven PIONEER 6
Presenters: John B. Buse, MD, PhD; Vanita R. Aroda, MD; Richard E. Pratley, MD; Stephen C. Bain, MA, MD, FRCP; Mansoor Husain, MD, FRCPC; Ofri Mosenzon, MD, MSc; Vivian Fonseca, MD.
Tuesday 11 June: 9:45–11:45
The positive topline results of the PIONEER 6 cardiovascular safety trial were press released late last year, but the full results are to be presented at the American Diabetes Association's 79th Scientific Sessions (ADA 2019). The investigators will also review data from the rest of the PIONEER program, outlining oral semaglutide’s efficacy and safety.
- News story | PIONEER 2, PIONEER 4 show benefits of oral semaglutide in type 2 diabetes
- External link | Published design and baseline characteristics of PIONEER 6
- News story | PIONEER 3: Oral semaglutide proves worth against sitagliptin
- Quick guide | Round-up of the GLP-1 receptor agonist CV outcome trials